Colorectal Cancer (CRC) Completed Phase 1 Trials for Cyclophosphamide (DB00531)

Back to Colorectal Cancer (CRC)

Also known as: Malignant Neoplasm of Colorectum / CRC, Colorectal Cancer / Colorectal Cancer / Cancer, Colorectal / CRC (Colorectal Cancer) / Colorectal, Cancer / Colo-rectal Cancer / Colorectal Cancers / A. Colorectal Cancer / Cancer Colorectal / Gastrointestinal Cancers - Colorectal / CRC / CRCS / Malignant colorectal neoplasm / Malignant neoplasm of cecum and/or colon and/or rectum / Malignant neoplasm of caecum and/or colon and/or rectum / Malignant neoplasm of cecum and/or colon and/or rectum (disorder) / Malignant neoplasm of large intestine / Malignant tumor of large intestine / Malignant tumour of large intestine / Malignant neoplasm of large intestine (disorder) / Malignant neoplasm of colon, unspecified / Malignant large intestinal neoplasm NOS / Cancer of large intestine / Malignant neoplasm of large intestine, NOS / Cancer of large bowel / CA - Cancer of large bowel / Colorectal neoplasms malignant / Malignant neoplasm of colon and/or rectum (disorder) / Large intestine carcinoma / Colorectal carcinoma / Colorectal cancer NOS

Indication	Status	Phase
DBCOND0031867 (Colorectal Cancer (CRC))	Completed	1

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT05415475	Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors	Treatment	CEA CAR-T cells (DB33283) Cyclophosphamide (DB00531) Fludarabine (DB01073)
NCT05396300	A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors	Treatment	CEA CAR-T cells (DB33283) Cyclophosphamide (DB00531) FAST CEA-targeted CAR-T (DB32832) Fludarabine (DB01073)
NCT01064375	Safety Study of DNA Vaccine Delivered by Intradermal Electroporation to Treat Colorectal Cancer	Treatment	Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583) Cyclophosphamide (DB00531)
NCT02963831	A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies	Treatment	Cyclophosphamide (DB00531) Durvalumab (DB11714) ONCOS-102 (DB17274)
NCT03841110	FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors	Treatment	Aldesleukin (DB00041) Atezolizumab (DB11595) Cyclophosphamide (DB00531) FT500 (DB30080) Fludarabine (DB01073) Nivolumab (DB09035) Pembrolizumab (DB09037)
NCT00656123	Study of Colon GVAX and Cyclophosphamide in Patients With Metastatic Colorectal Cancer	Treatment	Cyclophosphamide (DB00531)
NCT04426669	A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering	Treatment	Aldesleukin (DB00041) Coenzyme M (DB09110) Cyclophosphamide (DB00531) Fludarabine (DB01073) Tumor-infiltrating lymphocytes (DB30770)
NCT02298946	AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer	Treatment	AMP-224 (DB15767) Cyclophosphamide (DB00531)